JAK2 inhibitors are particularly used in the subgroup of B-ALL with JAK2, EPOR, CRLF2 and TSLP aberrations, while JAK1 and JAK3 inhibitors selectively inhibit patients with IL2RB gene rearrangements. This evidence concerns the gene TSLP and acute lymphoblastic leukemia.